Showing posts with label disease. Show all posts
Showing posts with label disease. Show all posts

Thursday, May 30, 2013

Don't Eat The Sausage - Sick Pigs = Your Food. #PEDV Is Effecting The US #Pork Industry

So basically all the pork in our grocery stores is from pigs that have this swine PEDV.  Yeah OKAYYYY!! Like we should really put diseased pork into our bodies.... sounds real healthy (sarcasm)! There is just something about this sentence below that sounds a loud effing horn that says .... THEY ARE IDIOTS...... DON'T LISTEN TO THEM... I REPEAT... DO NOT LISTEN TO THEM.    I like how they begin the article with this too..

"The swine-only virus, the Porcine Epidemic Diarrhea Virus (PEDV), poses no danger to humans or other animals, and the meat from infected pigs is safe for people to eat."    - F YOU!!!   

I would like to make a BLT for the person who said this and watch them eat it...Yummy BACON!!! Not just any old bacon... DISEASED BACONNNN!!



ARTICLE HIGHLIGHTS

  • "Like everything else, we screw up from time to time," said Ronald L. Plain, professor of agricultural economics at University of Missouri in Columbia, Missouri. "We know so little about the transmittal of this virus. We can't be sure if it's happening because of something we're supposed to do right and didn't - or by some mechanism we don't know that we're supposed to do differently."  This statement says a lot... they know so little about the virus.  I don't think it's just a lack of knowledge on how it's spread, but a lack of knowledge about the in's & out's of the virus.  It's never been a problem, so there's been no real research done on PEDV.  So, with that said, how can they be certain that this virus poses no risk to humans?  Just because someone  eats some diseased meat and doesn't initially show signs of sickness, doesn't mean that the person will never be effected (years from now). It just can't be a good idea to eat diseased meat; any kind of meat.

  • "But the food shield is not impermeable. "If it becomes clear that this is not a novel way for to be transmitted, and that there had to be physical contact, that's going to be a major concern," said William Marler, a leading food-safety attorney. "It means that there was a failure in the system."  the system fails us all the time... that's not new news.  They know nothing about this virus. 

  •  "Initial reporting about the virus may have been delayed, say sources, because its symptoms can be confused with a more common malady, transmissible gastroenteritis (TGE)"  It's actually sad that there are all these animals that are sick and suffering and just loaded up with antibiotics to stay alive until they are slaughtered.  It's just not right.


  • "Also, states are not required to report cases of PEDV to the federal government, and farmers are not required to report to state veterinarians."  Why the hell not?? That's just not wise.  Any sick animal(s) that will be going into the food supply should have to report these conditions.  But wait... now that I think about it, the majority of farm animals are sick. There would be an overload of cases and not enough man power to investigate.  I just answered my question





Chicago | Tue May 28, 2013 3:11pm EDT
(Reuters) - The sudden and widespread appearance of a swine virus deadly to young pigs - one never before seen in North America - is raising questions about the bio-security shield designed to protect the U.S. food supply.
The swine-only virus, the Porcine Epidemic Diarrhea Virus (PEDV), poses no danger to humans or other animals, and the meat from infected pigs is safe for people to eat.
Though previously seen in parts of Asia and Europe, the virus now has spread into five leading hog-raising U.S. states. How it arrived in the United States remains a mystery.
While the U.S. imports millions of pigs each year from Canada, it imports pigs from virtually no other country, and no Canadian cases of PEDV have been confirmed. Veterinarians and epidemiologists say pigs are infected through oral means, and that the virus is not airborne and does it not occur spontaneously in nature.
In recent years, with the emergence of dangerous pathogens such as H1N1, also known as swine flu, and bovine spongiform encephalopathy (BSE) or mad cow disease, the United States and other countries have sought to secure defenses both on the farm and at the national borders to protect against barnyard epidemics.
"We're just trying to get a handle on what's happening," said Tom Burkgren, executive director of the American Association of Swine Veterinarians. "It's like drinking water out of a fire hose. We're getting hits from all over the place."
Overall numbers of confirmed cases and mortality rates are not yet available, though anecdotal evidence suggests there are devastating losses for farms that are hit.
"If you've got it, it's bad," said Mark Greenwood, vice president of agri-business capital at AgStar Financial Services, who said none of his clients have been affected. "I spoke to a farmer in the Midwest who had it show up in a 2,000-head barn of pigs, and had a 40 percent death loss."
A spokeswoman for U.S. Department of Agriculture's Animal and Plant Health Inspection Service told Reuters the agency is working with state agencies and pork industry officials to discover where the virus originated.
THE VIRUS SPREADS
Confirmed cases have been reported in five hog-raising states including Iowa, the largest U.S. hog producer with 20 million hogs, according to the USDA. While only seven farms have had confirmed cases since May 17, more cases are expected as labs sift through samples, say sources investigating the outbreak.
Colorado, Indiana, Illinois and Minnesota reportedly have positive tests for PEDV, according to state veterinarians and agriculture department officials, and the National Veterinary Services Laboratory in Ames, Iowa.
PEDV, most often fatal to very young pigs, causes diarrhea, vomiting and dehydration. It also sickens older hogs, though their survival rate tends to be high.
Known as a "coronavirus" because of the crown-like spikes on its surface, the virus afflicted Chinain recent years and killed more than 1 million piglets.
PEDV is spread most commonly by pigs ingesting contaminated feces. Investigators are focused on physical transmission, perhaps a PEDV infected pig, equipment marred with feces, or even a person wearing dirty boots or with dirty nails.
The mystery about how the virus entered the United States is raising concern about potential holes in the bio-security shield designed to protect the U.S. food and farming sectors.
"Like everything else, we screw up from time to time," said Ronald L. Plain, professor of agricultural economics at University of Missouri in Columbia, Missouri. "We know so little about the transmittal of this virus. We can't be sure if it's happening because of something we're supposed to do right and didn't - or by some mechanism we don't know that we're supposed to do differently."
Initial reporting about the virus may have been delayed, say sources, because its symptoms can be confused with a more common malady, transmissible gastroenteritis (TGE).
Also, states are not required to report cases of PEDV to the federal government, and farmers are not required to report to state veterinarians.
As part of its assessment of the situation, USDA will email epidemiological surveys to swine veterinarians who are dealing cases of PEDV. Meanwhile, the veterinarians are sending samples to diagnostic labs, where technicians are scrambling gathering the tools needed to check the samples for PEDV - supplies many labs did not have prior to the outbreak.
While most farmers are taking a wait-and-see approach, some told Reuters they are turning away unnecessary visitors and double checking to ensure their safety protocols are being followed.
LOOKING NORTH
The search for leads also has turned to the nation's borders and ports of entry - specifically, Canada, where the United States imported 5.7 million head of live hogs last year.
Canada has never had a confirmed case of the virus, though it does not test for it, government officials told Reuters.
"Canada has very effective import measures in place to address this risk," said Dr. Rajiv Arora, senior staff veterinarian for the Canadian Food Inspection Agency's foreign animal disease section.
Canada can import live breeding pigs, under permits, from either the United States or the European Union, Arora said. The animals are quarantined by CFIA for a period of time, then inspected and tested - although not for PEDV - before released.
Canada imported C$1.7 million ($1.6 million) worth of live swine in 2012, including both slaughter-ready and breeder pigs, according to Canada's Agriculture Department.
CHINA HARD HIT
Veterinarians and agricultural epidemiologists in the United States are drawing grim lessons from the devastating effect PEDV has had in other countries where it has hit.
The first reports of suspected PEDV came in 1971 in the United Kingdom. As years passed, PEDV spread across parts of Europe and Asia. Veterinary researchers later concluded that lax bio-security measures contributed to PEDV's spread in Asia.
One of the worst known outbreaks of the virus hit China's pig herds in late 2010, according to the Centers for Disease Control and Prevention's Emerging Infectious Diseases Journal. Vaccines had limited effectiveness and PEDV over ran southern China killing more than 1 million piglets. The death rate for virus-infected piglets ranged from 80 percent to 100 percent.
Biosecurity measures in the U.S. food supply have been beefed up over the years, and especially after the outbreaks of mad cow disease and swine flu. Both outbreaks posed risks to human health.
Today, trucks carrying live animals are supposed to be cleaned before entering and leaving farms. At commercial hog operations, visitors routinely shower and change clothing before stepping into a barn. Overseas visitors typically wait several days before being in the presence of a commercially raised hog.
But the food shield is not impermeable. "If it becomes clear that this is not a novel way for to be transmitted, and that there had to be physical contact, that's going to be a major concern," said William Marler, a leading food-safety attorney. "It means that there was a failure in the system."

(Additional reporting by Rod Nickel in Winnipeg, Alexandra Harney in Tokyo, and Mark Weinraub, Theopolis Waters and Alyce Hinton in Chicago.; Editing by David Greising, Mary Milliken and Leslie Gevirtz)

Wednesday, January 9, 2013

LDN to treat Autoimmune Diseases - Clinical Trials

LDN Clinical Trials:
Logo LDNscience.org
'via Blog this'



Clinical Trials


Am J Gastroenterol. 2007 Apr;102(4):820-8. Epub 2007 Jan 11.
Low-dose naltrexone therapy improves active Crohn's disease.
Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS.
Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.
OBJECTIVES: Endogenous opioids and opioid antagonists have been shown to play a role in healing and repair of tissues. In an open-labeled pilot prospective trial, the safety and efficacy of low-dose naltrexone (LDN), an opioid antagonist, were tested in patients with active Crohn's disease.
METHODS: Eligible subjects with histologically and endoscopically confirmed active Crohn's disease activity index (CDAI) score of 220-450 were enrolled in a study using 4.5mg naltrexone/day. Infliximab was not allowed for a minimum of 8 wk prior to study initiation. Other therapy for Crohn's disease that was at a stable dose for 4 wk prior to enrollment was continued at the same doses. Patients completed the inflammatory bowel disease questionnaire (IBDQ) and the short-form (SF-36) quality of life surveys and CDAI scores were assessed pretreatment, every 4 wk on therapy and 4 wk after completion of the study drug. Drug was administered by mouth each evening for a 12-wk period.
RESULTS: Seventeen patients with a mean CDAI score of 356 +/- 27 were enrolled. CDAI scores decreased significantly (P=0.01) with LDN, and remained lower than baseline 4 wk after completing therapy. Eighty-nine percent of patients exhibited a response to therapy and 67% achieved a remission (P < 0.001). Improvement was recorded in both quality of life surveys with LDN compared with baseline. No laboratory abnormalities were noted. The most common side effect was sleep disturbances, occurring in seven patients.
CONCLUSIONS: LDN therapy appears effective and safe in subjects with active Crohn's disease. Further studies are needed to explore the use of this compound.
PMID: 17222320

Integr Cancer Ther. 2007 Sep;6(3):293-6.
Reversal of signs and symptoms of a B-cell lymphoma in a patient using only low-dose naltrexone.
Berkson BM, Rubin DM, Berkson AJ.
Integrative Medical Center of New Mexico, Las Cruces, USA.
PMID: 17761642

Mult Scler. 2008 Sep;14(8):1076-83.
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G.
Institute of Experimental Neurology (INSPE) and Department of Neurology, San Raffaele Scientific Institute, Via Olgettina 58, Milan, Italy.
A sixth month phase II multicenter-pilot trial with a low dose of the opiate antagonist Naltrexone (LDN) has been carried out in 40 patients with primary progressive multiple sclerosis (PPMS). The primary end points were safety and tolerability. Secondary outcomes were efficacy on spasticity, pain, fatigue, depression, and quality of life. Clinical and biochemical evaluations were serially performed. Protein concentration of beta-endorphins (BE) and mRNA levels and allelic variants of the mu-opiod receptor gene (OPRM1) were analyzed. Five dropouts and two major adverse events occurred. The remaining adverse events did not interfere with daily living. Neurological disability progressed in only one patient. A significant reduction of spasticity was measured at the end of the trial. BE concentration increased during the trial, but no association was found between OPRM1 variants and improvement of spasticity. Our data clearly indicate that LDN is safe and well tolerated in patients with PPMS.
PMID: 18728058

Pain Med. 2009 May-Jun;10(4):663-72. Epub 2009 Apr 22.
Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study.
Younger J, Mackey S.
School of Medicine, Department of Anesthesia, Division of Pain Management, Stanford University, 780 Welch Road, Suite 208, Palo Alto, CA 94304-1573, USA.
OBJECTIVE: Fibromyalgia is a chronic pain disorder that is characterized by diffuse musculoskeletal pain and sensitivity to mechanical stimulation. In this pilot clinical trial, we tested the effectiveness of low-dose naltrexone in treating the symptoms of fibromyalgia.
DESIGN: Participants completed a single-blind, crossover trial with the following time line: baseline (2 weeks), placebo (2 weeks), drug (8 weeks), and washout (2 weeks).
PATIENTS: Ten women meeting criteria for fibromyalgia and not taking an opioid medication.
INTERVENTIONS: Naltrexone, in addition to antagonizing opioid receptors on neurons, also inhibits microglia activity in the central nervous system. At low doses (4.5 mg), naltrexone may inhibit the activity of microglia and reverse central and peripheral inflammation.
OUTCOME MEASURES: Participants completed reports of symptom severity everyday, using a handheld computer. In addition, participants visited the lab every 2 weeks for tests of mechanical, heat, and cold pain sensitivity.
RESULTS: Low-dose naltrexone reduced fibromyalgia symptoms in the entire cohort, with a greater than 30% reduction of symptoms over placebo. In addition, laboratory visits showed that mechanical and heat pain thresholds were improved by the drug. Side effects (including insomnia and vivid dreams) were rare, and described as minor and transient. Baseline erythrocyte sedimentation rate predicted over 80% of the variance in drug response. Individuals with higher sedimentation rates (indicating general inflammatory processes) had the greatest reduction of symptoms in response to low-dose naltrexone.
CONCLUSIONS: We conclude that low-dose naltrexone may be an effective, highly tolerable, and inexpensive treatment for fibromyalgia.
PMID: 19453963

Inflamm Bowel Dis.. [Epub ahead of print]
Low-dose naltrexone for treatment of duodenal Crohn's disease in a pediatric patient.
Shannon A, Alkhouri N, Mayacy S, Kaplan B, Mahajan L.
Department of Pediatric Gastroenterology, Cleveland Clinic Pediatric Institute, Cleveland, Ohio.
PMID: 20014017

Annals of Neurology, Volume 9999, Issue 999A, Feb 2010
Pilot trial of low dose naltrexone and quality of life in MS
Bruce A.C. Cree, Elena Kornyeyeva, Douglas S. Goodin
Multiple Sclerosis Center at Univ. of Calif. in San Francisco 350 Parnassus Ave., Suite 908, San Francisco, CA 94117  USA
Objective: To evaluate the efficacy of 4.5 mg nightly naltrexone on the quality of life of multiple sclerosis patients.
Methods: This single center, double-masked, placebo-controlled, crossover studied evaluated the efficacy of eight weeks of treatment with 4.5 mg nightly naltrexone (Low dose naltrexone or LDN) on self reported quality of life of MS patients.
Results: 80 subjects with clinically definite multiple sclerosis were enrolled and 60 subjects completed the trial. 10 withdrew before completing the first trial period: 8 for personal reasons, 1 for a non-MS related adverse event and 1 for perceived benefit. Database management errors occurred in 4 other subjects and quality of life surveys were incomplete in 6 subjects for unknown reasons. The high rate of subject dropout and data management errors substantially reduced the trial's statistical power. LDN was well tolerated and serious adverse events did not occur. LDN was associated with significant improvement on the following mental health quality of life measures: a 3.3 point improvement on the Mental Component Summary score of the SF-36 (P=.04), a 6 point improvement on the Mental Health Inventory (P<.01), a 1.6 point improvement on the Pain Effects Scale (P=.04) and a 2.4 point improvement on the Perceived Deficits Questionnaire (P=.05).
Interpretation: LDN significantly improved mental health quality of life indices. Further studies with LDN in MS are warranted.
_______________________________________________________________________________
Who is LDNscience?  This is what they say......
Logo LDNscience.org
medinsight_logo_1
LDNscience™ is a public information project of theMedInsight® Research Institute.
The MedInsight® Research Institute is a U.S.-based 501(c)(3) nonprofit working to bridge the ever-widening gap between medical research and actual medical practice. We are dedicated to bringing relief to those who suffer from cancer or chronic medical conditions by raising awareness of:
  • • Commercially unsponsored medications.
  • • Off-label or secondary uses for approved medications.
  • • Specialized tests that enable treatments to be tailored to the individual.
MedInsight's co-founder, Moshe Rogosnitzky, is an expert in the clinical application of Low Dose Naltrexone (LDN)Opioid Growth Factor (OGF) and related therapies, which have made incredible inroads with Crohn’s disease, cancer and other serious diseases. He collaborates in research with the discoverers of LDN and OGFDr. Ian S. Zagon and Dr. Patricia J. McLaughlin of Hershey Medical Center, Penn State University, as well as with Dr. Jill P. Smith of Hershey Medical Center, who conducts clinical research into LDN and OGF.
This site is intended to provide you with general information on the background, use of and evidence forLDNOGF and related therapies, and to answer any questions on these therapies and our work.  If you cannot find the answer to your particular question, please submit your question and we will respond to you as soon as possible.
To become a much-valued supporter of this site or of our life-changing research into LDNOGF and related therapies, please visit:  Join Our Supporters.
medinsight_logo_1Thank you,
The LDNscience™ Team


Saturday, May 21, 2011

Your Gut's Digestion Process - Is it increasing your risk of CardioVascular Disease?


Hmmmmmm.  this just makes me think about how all our organs are connected and the health and state of functioning of one organ, will impact the working of another.  Just the way a machine would work.

Stanley Hazen, MD, PhD, and Zeneng Wang, PhD,Cell Biology, and colleagues at the Lerner Research Institute have discovered a new pathway that links a common dietary lipid and gut flora (microbes that reside in intestines) to the development of cardiovascular disease (CVD). This research was published in the April 8, 2011, issue of Nature.
Aside from genetic factors that increase a person's risk of CVD,environmental factors can also influence the disease. Familiar environmental factors include a diet rich in triglycerides and sterols (ex. cholesterol), which are two of the three main types dietary lipids. This current study discovered the importance of the third category of dietary lipids called "phospholipids" to heart disease.
Dr. Hazen's group looked at the interplay of dietary phospholipid, namely phosphatidyl choline (also called lecithin) and another category of environmental factors called microbes that reside in intestines. These gut flora play a largely beneficial role, promoting digestion and absorption of important nutrients. They do this by breaking down the food we eat into its byproducts, or metabolites. However, this study of over 2000 patients found that blood levels of three metabolites of lecithin (choline, trimethylamine N-oxide (TMAO), and betaine) strongly associated with risk of CVD. Feeding these metabolites to mice also caused atherosclerosis.
Healthy amounts of choline, TMAO, and betaine, are found in many fruits, vegetables, fish, and animal and dairy products. These three metabolites are also commonly marketed as direct-to-consumer supplements, supposedly offering increased brain health, weight loss, and/or muscle growth.
Choline is itself a natural semi-essential vitamin, although Hazen's group shows that when taken to excess, it promotes atherosclerotic heart disease in animal models, and associates with increased CVD risk in humans. "Over the past few years we have seen a huge increase in the addition of choline into multivitamins – even those marketed to our children – yet it is this same substance that our study shows the gut flora can convert into something that has a direct, negative impact on heart disease risk by forming an atherosclerosis-causing by-product," says Dr. Hazen.
"Knowing that gut flora generates a pro-atherosclerotic metabolite from a common dietary lipid opens up new opportunities for improved diagnostics, prevention, and treatment of heart disease, adds Dr. Hazen. "It also appears there is a need for considering the risk versus benefits of some commonly used supplements."

Saturday, May 7, 2011

A Short Article That Says A Lot About LDN


I like this short article because it covers the history of the drug LDN, how it started to get used for autoimmune diseases and why the FDA hasn't approved it for conditions other than drug addiction.  This article is from 2007 however, it's now 2011 and people still haven't heard about low dose naltrexone as an alternative treatment for many diseases.  I began doing research for SAFE and effective treatment for Crohn's Disease because I was on Remicade.  In my opinion, Remicade and other biologic drugs that weaken the immune system are not SAFE options.  Read the side-effect and safety indications for any of the biologics that are being used for many inflammatory diseases.  After reading this for yourself, you will understand why I consider this an unsafe treatment. Next, look up the side-effect and safety warnings for LDN/naltrexone.  
Now which one would you choose ?   

LDN - An Emerging Treatment - Article By Carl Frankel, Care2 Green Living contribution writer
If you’re one of the millions of people with auto-immune disease, there may be help for you. It’s a drug with a mouthful of a name—Low-Dosage Naltrexone, or LDN for short.
LDN is best known for its effect on multiple sclerosis. Thousands of people with MS are persuaded that it has halted the disease’s downward progression, and even reversed their symptoms. People with lupus, fibromyalgia, chronic fatigue syndrome, Crohn’s disease, and psoriasis also report benefits.
The good news doesn’t stop here. LDN is affordable—a bit over a dollar a day. Side effects——and many people don’t have them—are mild and short-term. It’s even FDA-approved, sort of. (It has “off-label” approval, meaning the FDA okayed it for a different purpose.)
The story of LDN is an intriguing saga of one man’s pioneering work, followed by a grass-roots, Internet-driven movement.
Naltrexone, without the “low-dosage” part, was developed by Dupont to treat drug addition, and approved in 1984 by the FDA for that purpose. The standard dosage was 50 milligrams, and it didn’t pan out as a treatment. Naltrexone blocks the opiate receptors in the brain. It works, in other words, by taking the fun out of taking opiates. The problem is, it takes the fun out of just about everything else, too. The result: People wouldn’t stay with the program.
Bernard Bihari, a Harvard-trained neurologist, began researching naltrexone and discovered something remarkable. When people took the drug in very low doses (3.0—4.5 milligrams instead of the standard 50 mg. dosage), it appeared to have a dramatic effect on auto-immune diseases. Bihari hypothesized that this essentially homeopathic dosage caused the body to manufacture more endorphins, which are centrally involved in supporting and regulating the immune system. He also came to believe it helped fight cancer and HIV.
Over the past 15 years or so, many thousands of people have taken LDN, to positive effect. The “anecdotal” evidence, so-called because it’s derived from stories, not studies, is overwhelmingly positive. It is also hugely persuasive, if you’re not the sort of person (your typical doctor, for instance) who requires clinical trials to be persuaded.
Where has the medical establishment been during this explosion of grassroots interest? Until recently, unmotivated and indifferent. Because the patent has expired and the drug is so inexpensive, there’s little money to be made from LDN, and therefore little reason to conduct clinical trials.
This can make it difficult to get a prescription for LDN. Because it hasn’t been clinically proven to be an effective auto-immune disease treatment, many doctors won’t prescribe it.
Recently, the medical establishment has started turning its attention to LDN, for a very simple reason: The anecdotal evidence is that overwhelming. Three national conferences on LDN have been held, and clinical trials have been launched in the United States and elsewhere. The first study to report results came out of Penn State University: “LDN therapy appears effective and safe in subjects with active Crohn’s disease.”
If you’re interested in learning more about LDN, a wealth of information is available at
www.ldninfo.org.
As for whether or not to try LDN, at the end of the day, there’s only one person who knows what’s right for you. And that’s you.
Carl Frankel is a journalist and author who has been writing about green business, green products, and integral living for the past 20 years.
More on Alternative Therapies (184 articles available)
More from Carl Frankel (12 articles available)


Read more: http://www.care2.com/greenliving/ldn-an-emerging-treatment.html#ixzz1LfORWCGV

Friday, April 22, 2011

Voices of Crohn's Disease Patients

This is good!  I found this on nytimes.com and it's men and women talking about their life living with Crohn's Disease.  Stuff like this, helps me to not feel so alone and misunderstood.  I need to read (listen or watch) what other people with this disease are feeling and going through; it helps me.   The fact that other people do struggle with similar issues with Crohn's, helps me to feel validated and not like such an outcast.

http://www.nytimes.com/interactive/2008/08/27/health/healthguide/TE_CROHNS_CLIPS.html

Sunday, April 10, 2011

LDN Study/Trial for Active Crohn's - *link*

Low Dose Naltrexone study results - show that LDN did help Crohn's Disease sufferers. 


I'm searching to find out why this drug that is said to help people with autoimmune diseases - Crohn's being just one of the diseases, is not approved by the FDA yet for the treatment of autoimmune diseases.

There are so many positives for prescribing this drug vs all the biologics that come with the risk of some very dangerous side effects. Not to mention, naltrexone is super reasonable in price, few side-effects and is effective!

I just wanted to share my findings when searching on the FDA site for clinical trials. Let me know if you find this encouraging or helpful to you.